4/20
11:17 am
zntl
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target [Yahoo! Finance]
Low
Report
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target [Yahoo! Finance]
4/17
03:15 pm
zntl
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
Medium
Report
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
4/10
09:28 am
zntl
Zentalis Pharmaceuticals (ZNTL) had its price target raised by Guggenheim from $6.00 to $10.00. They now have a "buy" rating on the stock.
High
Report
Zentalis Pharmaceuticals (ZNTL) had its price target raised by Guggenheim from $6.00 to $10.00. They now have a "buy" rating on the stock.
4/9
08:00 am
zntl
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
High
Report
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
4/9
06:06 am
zntl
Zentalis Pharmaceuticals (ZNTL) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
High
Report
Zentalis Pharmaceuticals (ZNTL) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
4/1
05:00 pm
zntl
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28
01:05 am
zntl
Low
Report
3/27
08:58 am
zntl
Zentalis Pharmaceuticals (ZNTL) had its "buy" rating reaffirmed by Guggenheim. They now have a $6.00 price target on the stock.
High
Report
Zentalis Pharmaceuticals (ZNTL) had its "buy" rating reaffirmed by Guggenheim. They now have a $6.00 price target on the stock.
3/26
04:05 pm
zntl
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
High
Report
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
3/17
05:14 pm
zntl
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 [Yahoo! Finance]
Medium
Report
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 [Yahoo! Finance]
3/17
04:30 pm
zntl
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Medium
Report
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
3/17
10:09 am
zntl
Zentalis Pharmaceuticals (ZNTL) is now covered by Wells Fargo & Company. They set an "equal weight" rating and a $5.00 price target on the stock.
Low
Report
Zentalis Pharmaceuticals (ZNTL) is now covered by Wells Fargo & Company. They set an "equal weight" rating and a $5.00 price target on the stock.
2/18
08:00 am
zntl
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2/3
04:05 pm
zntl
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
Medium
Report
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference